Lobate-GN

Quick links to important sections

Lobate-GN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lobate-GN

Property Description
Active Ingredients Clobetasol Propionate, Neomycin
Form Topical Cream
Pharmacological Class Topical Corticosteroid, Aminoglycoside Antibiotic
General Purpose Managing severe inflammation combined with bacterial infection
Potency Super-high potency (Clobetasol component)

Lobate-GN is a combination medicine formulated as a topical cream intended exclusively for application to the skin, integrating two distinct active ingredients to treat inflammatory skin conditions. It is classified into two major pharmacological classes: a topical corticosteroid and an aminoglycoside antibiotic.


What is the Composition and Primary Purpose of Lobate-GN? (Ingredients and General Benefit)

Defining Composition and Class

The steroid component, Clobetasol Propionate, is recognized as one of the most potent agents available in topical dermatological therapy, belonging to the super-high potency class of corticosteroids. This high level of activity is clinically recognized for its rapid effect in controlling severe inflammation. The antibiotic component, Neomycin, is a semi-synthetic agent and is categorized as an aminoglycoside antibiotic.

Primary Therapeutic Purpose

The primary purpose of combining these two agents is to efficiently manage severely inflamed skin conditions, such as chronic dermatitis or eczema, that are complicated by, or prone to, secondary bacterial infection. The resulting effect is rapid stabilization of the compromised skin environment and control of microbial growth, making the product a highly focused option for external use.

Regulatory References

  1. Neomycin Drug Information (MedlinePlus)

What side effects are possible with Lobate-GN?

Possible Side Effects and Safety Information

The official safety profile for Lobate-GN is defined by the high potency of its Clobetasol Propionate component and the systemic absorption potential of the Neomycin component. The most commonly documented adverse reactions are local and dermatological.


Adverse Reaction Frequencies and System Classes

The frequency of reported adverse reactions is categorized in regulatory documents:

Classification Examples of Reactions
Most Common (ge 5%) Burning sensation at the application site.
Common (1% - <2%) Skin atrophy (thinning), pruritus (itching), irritation, erythema, and telangiectasia (visible capillaries).
System-Organ Classes Skin and Subcutaneous Tissue, Endocrine, Metabolism, Ear, and Renal Systems.

Serious and Systemic Safety Considerations

The risks for serious adverse reactions arise primarily from the systemic absorption of the active ingredients, which is generally associated with extensive or prolonged use. These serious reactions include Hypothalamic-Pituitary-Adrenal (HPA) axis suppression from the corticosteroid component. The Neomycin component carries documented risks of systemic toxicities, including Ototoxicity (damage to the auditory or vestibular system) and Nephrotoxicity (kidney damage).


Population-Specific Safety Notes

Official labeling includes safety notes for specific populations. Pediatric patients are noted to be more susceptible to systemic effects, such as HPA axis suppression, due to their larger skin surface-to-body mass ratio. Pregnancy classification for Clobetasol Propionate is Category C.


Safety-Related Restrictions

The regulatory profile specifies that the product is contraindicated for use in certain skin conditions, including rosacea and acne vulgaris. The risk of both local and systemic adverse reactions is officially stated to increase with long-term exposure, application over large areas of the body, or use under occlusive dressings.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose from this topical medication is primarily associated with excessive or prolonged use, which may lead to significant absorption of its components into the body. While unlikely from typical application, excessive use can cause serious systemic effects.

Documented Overdose Manifestations

Symptoms of overdose relate to the body's response to an excess of the potent corticosteroid and the potential toxicity of the antibiotic component:

  • HPA Axis Suppression: Excessive use may suppress the Hypothalamic-Pituitary-Adrenal (HPA) axis, resulting in secondary adrenal insufficiency or manifestations of hypercorticism (Cushing's syndrome).
  • Neomycin Toxicity: Significant systemic absorption of Neomycin, especially when applied to large body areas or compromised skin, carries a risk of irreversible ototoxicity (hearing damage) and nephrotoxic potential (kidney damage).

Emergency Response

The required treatment for topical overdose is symptomatic, as no specific antidote is available. Acute hypercorticoid symptoms are typically reversible. If chronic toxicity is confirmed, the corticosteroid should be withdrawn slowly to allow the HPA axis to recover.

When to Seek Immediate Medical Help

Seek immediate medical attention if you experience signs of significant systemic absorption or toxicity, including:

  • Signs of hypercorticism or adrenal insufficiency (such as unusual tiredness, severe dizziness, muscle weakness, or loss of appetite).
  • Symptoms that suggest Neomycin toxicity, such as hearing loss, ringing in the ears, or signs of kidney issues.
  • If the medication is accidentally swallowed or if local symptoms like burning, itching, or stinging worsen or persist.

Therapeutic Uses of Lobate-GN

What Lobate-GN Treats: Main Uses and Benefits

This product is relevant in contexts involving severe inflammatory skin conditions that are compounded by or susceptible to secondary bacterial infection. This product is commonly used in therapeutic domains that involve resistant dermatoses such as recalcitrant eczemas and certain forms of psoriasis where a secondary bacterial infection is present, suspected, or likely to occur.


Managing Severe, Recalcitrant Symptoms

This medication is applied in clinical settings that involve conditions characterized by periods of heightened symptoms and severe, chronic inflammation. It is commonly used to help with pronounced physical signs, including intense redness (erythema), swelling (edema), and the abnormal thickening of skin lesions. This supportive relief helps maintain a sense of stability when symptoms are more noticeable.

Treating Inflammation with Microbial Complications

The combination is applicable within clinical settings that involve acute or disruptive episodes where the primary inflammatory skin condition is complicated by a potential microbial component. Used when groups of symptoms appear suddenly or fluctuate, and combined support is needed, which supports the patient by promoting temporary stability in the affected skin environment.


Quick Fact: Focus on Intense Itching The anti-inflammatory component is commonly used to help with intense pruritus, relevant for managing symptoms that interfere with daily comfort, contributing to improved comfort during symptomatic periods.

Eligibility and Restrictions for Use

Who Can and Cannot Use Lobate-GN?

Eligibility for Lobate-GN (Clobetasol Propionate/Neomycin) is strictly defined by regulatory documents, particularly concerning contraindications and patient populations at risk of systemic absorption.

Contraindicated and Restricted Populations

Population Group Eligibility Status Regulatory Basis
Infants/Children Contraindicated under 2 years old Risk of systemic absorption
Primary Infections Contraindicated in primary viral infections (e.g., Herpes simplex) Steroid-related risk of exacerbation
Skin Conditions Contraindicated in Rosacea, Acne Vulgaris, Perioral Dermatitis Steroid-related risk of exacerbation
Allergy Contraindicated with known hypersensitivity to Clobetasol, Neomycin, or related drugs Absolute ban
Pregnancy Not Recommended Insufficient established safety data
Lactation Not Recommended Safety not established in breast milk

Use is permitted for adults and children aged 2 and older, but treatment duration is limited. Special caution is advised for elderly patients or those with renal impairment due to the increased potential for systemic absorption of the neomycin component. The cream must also not be applied to areas with pre-existing skin atrophy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes interactions documented in official government regulatory sources for the two active components of Lobate-GN, Clobetasol Propionate and Neomycin.


Pharmacokinetic and Pharmacodynamic Interaction Patterns

The most significant interaction concerns arise when the components are absorbed into the systemic circulation, a risk amplified by the super-high potency of the corticosteroid and application to compromised skin.

Component Interacting Substance Class Officially Documented Interaction Pattern
Clobetasol Propionate Strong CYP3A4 Inhibitors (e.g., ritonavir) Increased Systemic Exposure: Co-administration may significantly increase the plasma concentration of the Clobetasol component, raising the potential for systemic corticosteroid effects.
Neomycin Oto-/Nephrotoxic Medicines Additive Toxicity Risk: Concurrent use with other medicines known to damage the ear or kidney leads to an additive risk of toxicity.
Neomycin Neuromuscular Blocking Agents Potentiated Effects: Systemic absorption may enhance the actions of these agents, increasing the risk of neuromuscular blockade.

Co-administration with other corticosteroid-containing products is formally associated with an increased risk of cumulative systemic exposure to corticosteroids.

Interaction-Related Constraints

Official labeling documents identify specific population factors that increase interaction risk. Impaired renal function may reduce the clearance of systemically absorbed Neomycin, which exacerbates its toxic interactions. Conditions such as a compromised skin barrier or hepatic impairment increase the rate of systemic absorption of both active ingredients, thereby amplifying the potential for all systemic-based drug interactions. No mandatory timing-separation requirements or formal drug-drug contraindications are explicitly documented for this topical formulation.

Mechanism of Action

How Lobate-GN Works: Mechanism of Action

Steroid Modulation of Inflammatory Gene Expression

The corticosteroid component, Clobetasol, acts as an agonist for cytoplasmic Glucocorticoid Receptors (GRs). The activated Clobetasol-GR complex translocates to the nucleus and primarily suppresses the activity of pro-inflammatory transcription factors, such as NF-kappa B . This mechanism modifies the early molecular steps that shape the systemic outcome, resulting in a significant decrease in the production of inflammatory mediators and leading to vasoconstriction and local immunosuppression.

Bactericidal Interference with Protein Synthesis

The antibiotic component, Neomycin, is an aminoglycoside that binds irreversibly to the bacterial 30S ribosomal subunit. This binding causes errors in protein translation by promoting mRNA misreading. This interference leads to the synthesis of non-functional proteins, initiating signaling sequences that culminate in bacterial cell death and terminates the viability of susceptible bacteria.

Combined Mechanistic Effect

The formulation results in a combined mechanistic effect by engaging two distinct pathways simultaneously: gene-level immune suppression (Clobetasol) and protein synthesis inhibition (Neomycin). This simultaneous modulation of heightened immune signaling and microbial viability results in both immune suppression and bacterial eradication.

Dosage and Administration Information

How to Use Lobate-GN

Lobate-GN is a combination medicine containing Clobetasol Propionate (a super-high potency corticosteroid) and Neomycin (an aminoglycoside antibiotic) formulated exclusively as a topical cream for application to the skin.

Its use is governed by strict, short-term application principles to manage severe inflammatory conditions of the skin that are complicated by infection, with the goal of achieving rapid control.


Application and Dosage Principles

The cream is applied sparingly as a thin film and gently rubbed into the affected skin area. The initial frequency of application is typically once or twice daily, which should be reduced as the skin condition improves.

Treatment must be short-term; the overall duration of continuous use is generally limited to a maximum of four weeks. If no improvement is observed after seven days, the treatment should be reviewed.


Administration Constraints and Limits

The administration of Lobate-GN is subject to several constraints based on the Clobetasol component's high potency:

  • Weekly Dose Maximum: The total amount of cream applied must not exceed 50 grams per week for adult patients.
  • Occlusion Rule: The treated skin area must not be bandaged, covered, or wrapped with occlusive dressings unless specifically instructed otherwise, as this significantly increases absorption.
  • Restricted Areas: Application to the face is undesirable and should be limited to only a few days. Use is generally avoided in sensitive areas such as the eyes, axillae (armpits), and groin.
  • Pediatric Use: Use in children younger than two years is generally not recommended. For older children, the treatment course is limited to a maximum of five days.

Recent Clinical Evidence

Research evidence / Overview of Studies for Lobate-GN

This overview describes the clinical research structure for Lobate-GN (Clobetasol Propionate + Neomycin), detailing the types of studies conducted and the areas where scientific knowledge remains limited. This information is intended to provide context on the medicine's clinical evaluation and is strictly descriptive, not advisory.


Evidence for Severe Inflammatory Dermatoses Complicated by Infection

Research for this combination product has explored its use in conditions characterized by functional limitations, such as certain resistant forms of eczema or psoriasis, especially when they are associated with acute or disruptive episodes that involve a secondary bacterial component. The primary research conducted in this area involved short-term, randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time when using both the anti-inflammatory agent and the antibiotic together. In these trials, studies explored outcomes related to physical discomfort and outcomes linked to inflammatory or irritative states, such as the degree of visible redness, swelling, and the thickness of the skin lesions, measured using investigator assessments. Research also described the status of microbial presence in the lesions, which was an outcome relevant to the neomycin component. Findings describe patterns observed in the studies over short treatment intervals and studies contribute to the broader evidence landscape.

Focus of Clinical Studies: Outcomes Examined in Trials

Research examined a range of outcomes capturing phases of heightened symptom activity. In addition to evaluating changes in visible signs of inflammation (like redness and thickness), research explored patient-reported outcomes describing perceived discomfort, such as the intensity of itching. These outcomes reflect daily functioning or activity level during the symptomatic period. The collected data show patterns related to the temporary physiological change measured during the study period.

Trial Duration and Follow-up for Short-Term Use

The research base for Lobate-GN is derived from studies conducted during periods of increased symptom activity with limited follow-up durations. Typically, trials observed responses over defined time intervals of two to four consecutive weeks. This short-term research scenario is relevant for evaluating short-term symptom changes; however, it means that evidence is limited for long-term outcomes regarding the persistence of observed changes or patterns of symptom recurrence after the treatment period has ended. Certainty remains low regarding the available data on long-term symptom changes based on these short study windows.

Evidence in Specific Patient Groups and Subpopulations

Results apply only to the populations studied and do not automatically extend to other groups. Data for certain groups remain insufficient for this specific combination product. For instance, limited information is available for evaluating its application in children (particularly those under 12) or in pregnant or lactating women, and such usage is typically not addressed by the core clinical trials for this specific combination product.

Research Gaps and Areas of Uncertainty

The evidence highlights what is known—and what is still uncertain—about this research base. A primary limitation is the inherent short duration of the follow-up periods, which means the evidence is limited in providing insight into maintenance or relapse patterns. Furthermore, research examined various comparative scenarios against the steroid component alone, and the data show patterns related to observed differences in outcomes. Comparative evidence is lacking for many non-severe scenarios, and subgroup findings are uncertain, meaning research does not determine whether an individual will respond similarly across all potential clinical situations.

Frequently Asked Questions (FAQ)

Common questions about Lobate-GN (FAQ)


Q: What happens if I stop using Lobate-GN suddenly?

Official product information suggests that the recovery of the body’s natural hormone function, known as the HPA axis (Hypothalamic-Pituitary-Adrenal axis), is generally prompt once the topical corticosteroid component is stopped. Although the labels do not use the term 'withdrawal symptoms,' systemic effects like HPA suppression are monitored, which is why the treatment duration is typically kept short. Discussing the full scope of cessation with a healthcare provider is generally recommended.


Q: What should I do if I accidentally get Lobate-GN in my eyes?

Regulatory drug labels state clearly that this medication is strictly for external use and that contact with the eyes should be avoided. Specific advice for accidental exposure is best obtained from a healthcare provider or a poison control center, as immediate rinsing may be advised.


Q: Can I use Lobate-GN if I have diabetes?

Caution is generally advised for individuals who have conditions like diabetes mellitus or glucose intolerance. This is because the corticosteroid component in Lobate-GN can be absorbed into the body, which has the potential to influence blood sugar levels. The potential risks of systemic absorption are important factors for patients with diabetes to consider.


Q: Can I use makeup or moisturizer after applying Lobate-GN?

General patient information for topical corticosteroids, such as the one in Lobate-GN, often advises a waiting period before applying other products. For instance, some guidance recommends waiting at least 30 minutes after using the cream before applying other topical products like a moisturizer or makeup to ensure the medication is properly absorbed.


Q: Can Lobate-GN affect blood sugar levels?

Studies and regulatory documents indicate that the systemic absorption of the corticosteroid component may potentially affect blood sugar levels. This effect could diminish the effectiveness of medicines used to manage blood glucose, such as insulin or oral antidiabetic agents. Any changes in blood sugar or related concerns are generally discussed during a consultation with a prescribing physician.


Q: What happens if I miss an application of Lobate-GN?

Official patient instructions often state that if an application is missed, it can be used as soon as it is remembered. However, if it is almost time for the next scheduled application, the patient information typically states only the regular dose should be used, without applying extra to compensate for the missed one.


Q: Can Lobate-GN cause withdrawal symptoms if discontinued?

While regulatory language focuses on the potential for HPA axis recovery, some patient leaflets suggest caution when discontinuing the product after prolonged use. In such cases, a healthcare provider may advise gradually reducing the frequency of application to help the skin adjust and prevent a rebound reaction.


Q: Does Lobate-GN work for fungal infections?

Official regulatory warnings indicate that products containing Clobetasol Propionate are not indicated for primary fungal infections. The product is designed to manage inflammation that is complicated by a bacterial infection. If a fungal infection is present, a separate, appropriate antifungal treatment is generally required.


Q: Why is it important to wash hands before and after applying Lobate-GN?

Drug labels explicitly instruct users to wash their hands after each application of the cream. This practice helps ensure the medicine is only applied to the intended area and minimizes the risk of transferring the powerful active ingredients to other sensitive areas of the body or other people.


Q: Can I use Lobate-GN if I have a history of glaucoma?

The corticosteroid component should be used with caution in individuals with a history of glaucoma (increased pressure in the eye). Although this is a topical cream, prolonged use or use near the eyes may increase the risk of elevated intraocular pressure. The potential risks associated with this condition are a key consideration when the product is prescribed.


Q: Can I use Lobate-GN for rashes that are not infected?

The primary purpose of this combination product is to treat severe inflammation that is complicated by or susceptible to bacterial infection. While the steroid component addresses inflammation, the inclusion of the antibiotic component suggests its intended use is for situations where an infection is present or strongly suspected.


Q: How quickly should I expect to see an improvement after starting Lobate-GN?

Official guidance requires that a patient’s condition be reviewed if no improvement is observed after seven days of starting treatment. This timeline is an important clinical review marker. However, the regulatory labels do not specify a common or expected day-to-day timeline for when positive improvement typically begins.


Q: Why do doctors often prescribe Lobate-GN instead of separate medications?

The formulation is designed to provide a combined mechanistic effect by simultaneously engaging two distinct pathways: immune suppression from the corticosteroid and bacterial eradication from the antibiotic. This dual-action approach is often used to efficiently manage complex skin conditions where inflammation and infection are both present.


Q: Are there any known allergic reactions to the non-active ingredients in Lobate-GN?

Regulatory documents explicitly contraindicate use for individuals with a known hypersensitivity to the active ingredients (Clobetasol Propionate, Neomycin) or drugs related to them. This warning is generally understood to cover any component of the cream, including the non-active ingredients.


Q: What is the general safety classification of Lobate-GN?

Lobate-GN is classified based on the potency of its components. The Clobetasol component is defined as a super-high potency corticosteroid, which is associated with specific limits on use duration and application area. The overall safety profile includes warnings regarding systemic risks like HPA axis suppression and the pregnancy classification of Category C.


Q: Why are there warnings about using Lobate-GN near mucous membranes?

Warnings are in place because application to sensitive areas, such as the face, armpits, and groin, should be avoided or severely limited. These areas may have a higher rate of skin absorption than others, which increases the risk of the powerful active ingredients being absorbed into the body.


Q: What are the signs that Lobate-GN is starting to work?

Clinical studies examine several measurable outcomes to determine effectiveness. These outcomes include a visible decrease in the degree of redness, swelling, and the thickness of the skin lesions. Patient-reported outcomes also track changes in discomfort, such as a reduction in the intensity of itching.


Q: Is the absorption rate of Lobate-GN higher on certain parts of the body?

Regulatory restrictions confirm that the rate of absorption varies across the body. The risk of systemic absorption is higher when the cream is applied to areas with thinner skin or areas that are naturally occluded (covered), which is why application is restricted on areas like the face, armpits, and groin.

How should Lobate-GN be stored and disposed of?

Storage and Disposal Requirements

The storage of Lobate-GN Cream must adhere strictly to official regulatory guidelines to maintain its labeled quality and stability.

Storage and Disposal Requirement Official Mandate
Temperature and Environment Store below 25 C or 30 C and do not freeze.
Protection Conditions Must be protected from sunlight, light, moisture, and kept away from direct heat.
Packaging Keep the medicine in its original container and ensure it is tightly closed.
Child Safety Must be stored out of the sight and reach of children and pets.
Disposal Dispose of unused or expired medicine properly and according to local regulations (do not dispose via household waste or wastewater).

These instructions, mandated by regulatory authorities, ensure the product remains stable for the duration of its shelf-life and is discarded in an environmentally appropriate manner.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lobate-GN found in:

A-Z Index: